Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 10/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6703433 | 0.94 | TRPA1 (0.61) | TRPA1SMN1; SMN2RXFP1TP53ALDH1A1 | |
| SCHEMBL7033357 | 0.85 | SMN1; SMN2 (0.54) | TRPA1SMN1; SMN2TP53KDM4EALDH1A1 | |
| SCHEMBL6245168 | 0.82 | TRPA1 (0.62) | TRPA1SMN1; SMN2RXFP1KDM4EALDH1A1 | |
| SCHEMBL7032058 | 0.81 | MMP13 (0.53) | SMN1; SMN2KDM4EALDH1A1HSD17B10MEN1 | |
| SCHEMBL7034213 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2RXFP1TP53KDM4EALDH1A1 | |
| SCHEMBL7035476 | 0.79 | MAPT (0.53) | TRPA1SMN1; SMN2TP53KDM4EALDH1A1 | |
| SCHEMBL6731246 | 0.78 | TRPA1 (0.67) | TRPA1SMN1; SMN2RXFP1TP53KDM4E | |
| SCHEMBL6257817 | 0.78 | TRPA1 (0.66) | TRPA1SMN1; SMN2RXFP1TP53MEN1 | |
| SCHEMBL6517292 | 0.78 | MAPT (0.59) | SMN1; SMN2TP53KDM4EALDH1A1 | |
| SCHEMBL6254839 | 0.77 | TRPA1 (0.56) | TRPA1SMN1; SMN2RXFP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370562-A1 | THIENO[2,3-D]PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | HARTER WILLIAM GLEN (US) | 2003-01-02 | — | — | US | disclosed |
| WO-2002064598-A1 | THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004172-A1 | Fused pyrimidinone matrix metalloproteinase inhibitors | MMP13, MMP3, MMP25 | TRPA1 3888/4885SMN1; SMN2 2160/4885RXFP1 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.